Context: Increased circulating free fatty acids (FFAs) have been proposed to contribute to insulin resistance in obesity. Short-term studies have investigated the effects of acipimox, an inhibitor of hormone-sensitive lipase, on glucose homeostasis, but longer-term studies have not been performed. Objective: To test the hypothesis that long-term treatment with acipimox would reduce FFA and improve insulin sensitivity among nondiabetic, insulin-resistant, obese subjects. Design, Setting, Patients, and Intervention: At an academic medical center, 39 obese men and women were randomized to acipimox 250 mg thrice-daily vs identical placebo for 6 months. Main Outcome Measures: Plasma lipids, insulin sensitivity, adiponectin, and mitochondrial function via assessment of the rate of post-exercise phosphocreatine recovery on 31P-magnetic resonance spectroscopy as well as muscle mitochondrial density and relevant muscle gene expression. Results: Fasting glucose decreased significantly in acipimox-treated individuals (effect size,6 mg/dL; P
CITATION STYLE
Makimura, H., Stanley, T. L., Suresh, C., De Sousa-Coelho, A. L., Frontera, W. R., Syu, S., … Grinspoon, S. K. (2016). Metabolic effects of long-term reduction in free fatty acids with acipimox in obesity: A randomized trial. Journal of Clinical Endocrinology and Metabolism, 101(3), 1123–1133. https://doi.org/10.1210/jc.2015-3696
Mendeley helps you to discover research relevant for your work.